Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

Recent advancements in positron emission tomography (PET ... to select candidates for treatment with therapeutic agents like [177Lu]/[90Y]PentixaTher, which are designed to deliver targeted ...

Pluvicto (lutetium (177Lu) vipivotide tetraxetan ... Britain alongside Locametz (gozetotide), a PSMA-targeted positron emission tomography (PET) imaging tracer, which is used to identify patients ...

PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 385(12), 1091–1103.